A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T‑Cell Lymphoma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs BNZ 1 (Primary)
- Indications Cutaneous T cell lymphoma; Lymphoid leukaemia
- Focus Adverse reactions
- Sponsors Bioniz
- 30 Nov 2017 Planned initiation date changed from 15 Sep 2017 to 1 Dec 2017.
- 01 Aug 2017 Status changed from planning to not yet recruiting.
- 07 Jul 2017 New trial record